Medical Condition News

RSS

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Macular degeneration drug may cause increased IOP

Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

24 Oct 2011

NCI awards Metabolomx SBIR contract to develop sensor array system for detecting lung cancer

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, today announced the Company was awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined Phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

24 Oct 2011

Exploring palliative care's positives and negatives

What if a new medication for severely ill patients had no role in curing them but made them feel much better despite being sick?

24 Oct 2011

CryoLife begins enrollment in BioFoam Surgical Matrix IDE clinical trial

CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.

24 Oct 2011

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Pharmaceutical company Pharmaxis today announced the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care."

24 Oct 2011

Zeaxanthin reduces risk for AMD

St. Louis-based ZeaVision, LLC announced that three recent groundbreaking studies demonstrate that Zeaxanthin (zee-uh-zan-thin), the predominate protective pigment in the back of the eye, reduces the risk for Age-Related Macular Degeneration (AMD) and benefits the treatment of advanced AMD, a condition that destroys central vision and affects millions of Americans.

24 Oct 2011

Collagen crosslinking for keratoconus may receive FDA approval in 2012

Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other parts of the world.

24 Oct 2011

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Affymax, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for peginesatide proposed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis on December 7, 2011 during the afternoon session.

24 Oct 2011

HMS, EPFL to collaborate on 6 pioneering neuroengineering projects

Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.

24 Oct 2011

Holtorf Medical Group opens new affiliate center in King of Prussia, Pennsylvania

Holtorf Medical Group, California's leading integrative, evidence-based medical facility, is pleased to announce the opening of its newest affiliate center, Garabedian Medical Clinic in King of Prussia, Pennsylvania.

24 Oct 2011

Teleflex launches ArrowADVANTAGE pressure-injectable peripherally inserted central catheter

Teleflex Incorporated today announced the launch of the ArrowADVANTAGE pressure-injectable peripherally inserted central catheter.

24 Oct 2011

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced initiation of dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation.

24 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.

24 Oct 2011

FDA accepts Ironwood and Forest Laboratories' linaclotide NDA for review

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011

Simulation improves cardiac surgical training results

Residents in cardiac surgery who receive extra training on a take-home simulator do a better job once they get into the operating room, Dr. Buu-Khanh Lam today told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Medical Condition News

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Macular degeneration drug may cause increased IOP

NCI awards Metabolomx SBIR contract to develop sensor array system for detecting lung cancer

Exploring palliative care's positives and negatives

CryoLife begins enrollment in BioFoam Surgical Matrix IDE clinical trial

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Zeaxanthin reduces risk for AMD

Collagen crosslinking for keratoconus may receive FDA approval in 2012

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

HMS, EPFL to collaborate on 6 pioneering neuroengineering projects

Holtorf Medical Group opens new affiliate center in King of Prussia, Pennsylvania

Teleflex launches ArrowADVANTAGE pressure-injectable peripherally inserted central catheter

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

U-M researchers to study new approach in halting downward spiral of diabetes

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

FDA accepts Ironwood and Forest Laboratories' linaclotide NDA for review

SCI patients with autonomic dysfunction more likely to develop heart disease

Simulation improves cardiac surgical training results

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Neurofilament light as a translational biomarker

Latest News